Proinflammatory and "resiliency" proteins in the CSF of patients with major depression

Depression and Anxiety

Volumn 29, Issue 1, 2012, Pages 32-38

  Martinez, Jose M ^a   Garakani, Amir ^a   Yehuda, Rachel ^a,b   Gorman, Jack M ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b James J Peters Veterans Affairs   (United States)

^c Riverdale Behavioral Health Consultants   (United States)

Author keywords

brain derived neurotrophic factor; cerebrospinal fluid; cytokines; depression; neuropeptide Y

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; NEUROPEPTIDE Y; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; FEMALE; HUMAN; INFLAMMATION; LUMBAR PUNCTURE; MAJOR DEPRESSION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; NEUROPEPTIDE Y; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84856691723     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20876     Document Type: Article

References (51)

1. Raison Cl, Capuron L, Miller AH,. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2008; 27: 24-31. (Pubitemid 43083561)
2. Adler UC, Marques AH, Calil HM,. Inflammatory aspects of depression. Inflamm Allergy Drug Targets 2008; 7: 19-23. (Pubitemid 351688296)
3. Miller AH, Maletic V, Raison CL,. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
4. Dowlati Y, Herrmann N, Swardfager W,. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
5. Morales-Medina JC, Dumont Y, Quirion R,. A possible role of neuropeptide Y in depression and stress. Brain Res 2010; 1414: 194-205.
6. Eaton K, Sallee FR, Sah R,. Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem 2007; 7: 1645-1659. (Pubitemid 350131002)
7. Ishida H, Shirayama Y, Iwata M, et al. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007; 17: 271-280. (Pubitemid 46649579)
8. h by neuropeptide Y and corticotrophin-releasing factor in basolateral amygdala as a possible mechanism for their effects on stress-related behaviors. J Neurosci 2010; 30: 16970-16982.
9. Donschke K, Dannolowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010; 20: 301-309.
10. Frisch C, Hanke J, Kleinerüschkamp S, et al. Positive correlation between the density of neuropeptide y positive neurons in the amygdala and parameters of self-reported anxiety and depression in mesiotemporal lobe epilepsy patients. Biol Psychiatry 2009; 66: 433-440.
11. Carvajal C, Dumont Y, Quirion R,. Neuropeptide Y: role in emotion and alcohol dependence. CNS Neurol Disord Drug Targets 2008; 5: 181-195.
12. Nikisch G, Agren H, Eap CB, Czernik A, Baumann P, Mathé AA,. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 2005; 8: 403-410. (Pubitemid 41002494)
13. Matté AA, Husuam H, El Koury A, et al. Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities? Do neuropeptides play a role ? Physiol Behav 2007; 92: 226-231.
14. Madaan V, Wilson DR,. Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug News Perspect 2009; 22: 319-324.
15. Sah R, Ekhator NN, Strawn JR, et al. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol Psychiatry 2009; 66: 705-707.
16. Nikisch G, Mathé AA,. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry 2008; 23: 356-359.
17. Olsson A, Regnéll G, Träskman-Bendz L, Ekman R, Westrin A,. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment. Eur Neuropsychopharmacol 2004; 14: 479-485. (Pubitemid 39626896)
18. Sen S, Duman R, Sanacora G,. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
19. Dwivedi Y,. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat 2009; 5: 433-449.
20. Chen B, Dowlatshani D, MacQueen GM, Wang JF, Young LT,. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265. (Pubitemid 32778442)
21. Dwivedi YY, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN,. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinas B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804-815. (Pubitemid 36960912)
22. Brunoni AR, Lopes M, Fregni F,. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-1180.
23. Elfving B, Plougmann PH, Müller HK, Mathé AA, Rosenberg R, Wegener G,. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010; 13: 563-572.
24. Salehi Z, Mashayekhi F,. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci 2009; 16: 90-93.
25. Laske C, Stransky E, Leyhe T, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 2007; 41: 387-394. (Pubitemid 46187251)
26. Bonne O, Gill JM, Luckenbaugh DA, et al. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J Clin Psychiatry 2010; [Epub ahead of print].
27. Grundström E, Lindholm D, Johansson A, Blennow K, Ashmark H,. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000; 11: 1781-1783. (Pubitemid 30350353)
28. Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK, Svenningsson P,. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol 2010; 257: 524-532.
29. Graeber MB,. Changing face of microglia. Science 2010; 330: 783-788.
30. Anisman H, Merali Z,. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003; 35: 2-11. (Pubitemid 36356868)
31. Hayley S, Poulter MO, Merali Z, Anisman H,. The pathogenesis of clinical depression: stressor-and cytokine-induced alterations of neuroplasticity. Neuroscience 2005: 135: 659-678. (Pubitemid 41407732)
32. Zhu B-B, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA,. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010; 35: 2510-2520.
33. Seguin JA, Brrennan J, Mangano E, Hayley S,. Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration. Neuropsychiatr Dis Treat 2009; 5: 5-14.
34. Slavich GM, Way BM, Eisenberger NI, Taylor SE,. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci USA 2010; 107: 14817-14822.
35. Pace TW, Mletzko TC, Algabe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006; 163: 1630-1633. (Pubitemid 44465765)
36. Carpenter LL, Gawuga C, Tyrka AR, Lee JK, Anderson GM, Price LH,. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010; 35: 2617-2623.
37. Gill GP, Luckenbaugh D, Charney C, Vythilingham M,. Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. Biol Psychiatry 2010; 68: 999-1006.
38. Lehton SM, Niskanen L, Miettola J, Tolmunen T, Viinamäki H, Mäntyselkä P,. Serum anti-inflammatory markers in general population subjects with elevated depressive symptoms. Neurosci Lett 2010; 484: 201-205.
39. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20: 473-476. (Pubitemid 41489458)
40. Janssen DGA, Caniato RN, Verster JC, Baune BT,. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25: 201-215.
41. O'Brien SM, Scully P, Fitzgeral P, Scott LV, Dinan TG,. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326-331. (Pubitemid 44854992)
42. Uher R, Perroud N, Ng MY, et al. Genome-w-wide pharmacogenetics of antidepressants response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564.
43. Rapp MA, Schnaider-Berri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006; 63: 161-167. (Pubitemid 43213877)
44. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 2007; 68: 1902-1908. (Pubitemid 46848622)
45. Kop WJ, Stein PK, Tracy RP, Barzilay JI, Schulz R, Gottdiener JS,. Autonomic nervous system dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression. Psychosom Med 2010; 72: 626-635.
46. Dunn AJ,. Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 2006; 6: 52-68. (Pubitemid 44161126)
47. Kronfol Z, Remick DG,. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157: 683-694. (Pubitemid 30249643)
48. Schiepers OJ, Wichers MC, Maes M,. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 29: 201-217. (Pubitemid 40202906)
49. Beck AT, Kovacs M, Weissman A,. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 1979; 47: 343-352. (Pubitemid 9157284)
50. Oquendo MA, Halberstam B, Mann JJ,. Risk factors for suicidal behavior: utility and limitations of research instruments. In:, First MB, editor. Standardized Evaluation in Clinical Practice. Vol. 22. Washington, DC: American Psychiatric Publishing, Inc.; 2003.
51. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009; 66: 287-292.